Arbutus Biopharma shares are trading higher after the FDA granted the company Fast Track designation for imdusiran for the treatment of chronic hepatitis B

Benzinga Newsdesk www.benzinga.com Positive 95.2%

Neg 0% Neu 0% Pos 95.2%

Comments

No comments yet. Be the first!